Key facts
- This page summarizes Matthew L. Posard's Form 4 filing for Talis Biomedical Corp.
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 12 Jun 2023, 17:28.
Matthew L. Posard - 09 Jun 2023 Form 4 Insider Report for Talis Biomedical Corp
- Reporting relationship
- Director
- Issuer ticker
- N/A
- Reported as of
- 09 Jun 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 12 Jun 2023, 17:28:05 UTC
- Prior SEC filing
- 05 Jun 2023
- Next SEC filing
- 16 Jun 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Gillian Green, Attorney-in-fact for Matthew L. Posard
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Matthew L. Posard filed Form 4 for Talis Biomedical Corp on 12 Jun 2023.
Change
- Previous filing in this sequence was filed on 05 Jun 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
TLIS
transaction
Derivative
Stock option (right to buy)
Award
- Transaction value
- $0
- Shares
- +95,000
- Change %
- Price
- $0.000000
- Shares after
- 95,000
- Date
- 09 Jun 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 95,000
- Exercise price
- $0.5000
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
1/12th of the shares subject to the option shall vest monthly over one year from the vesting commencement date.